Ionis Pharmaceuticals IONS Gain (Loss) on Investments
Gain (Loss) on Investments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's gain (loss) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Ionis Pharmaceuticals's gain (loss) on investments?
- Ionis Pharmaceuticals (IONS) reported gain (loss) on investments of $22.58M in Q1 2026.
- How has Ionis Pharmaceuticals's gain (loss) on investments changed year-over-year?
- Ionis Pharmaceuticals's gain (loss) on investments increased by 1143.6% year-over-year, from -$2.16M to $22.58M.
- What is the long-term trend for Ionis Pharmaceuticals's gain (loss) on investments?
- Over 3 years (2021 to 2025), Ionis Pharmaceuticals's gain (loss) on investments has grown at a 0.4% compound annual growth rate (CAGR), from $10.1M to $10.22M.